Table 2 Survival rate at 2 years after allo-HSCT in the whole cohort (N = 153) according to the ABO blood type and conditioning regimens
Subgroups | MDS cohort (N = 153) | |||
|---|---|---|---|---|
OS (95% CI) | PFS (95% CI) | Relapse (95% CI) | NRM (95% CI) | |
Donor-recipient ABO blood type | ||||
 Compatible | 80.0% (71.4–89.8%) | 76.3% (67.2–86.6%) | 9.9% (4.3–18%) | 14% (7.3–22%) |
 Major/bidirectional incompatible | 64.0% (50.2–81.6%) | 58.5% (44.4–77.0%) | 19% (7.9–33%) | 23% (11–37%) |
 Minor incompatible | 79.2% (65.5–95.9%) | 77.1% (63.6–93.6%) | 10% (2.4–24%) | 13% (4.0–27%) |
 P-value | 0.088 | 0.042 | 0.276 | 0.481 |
Conditioning regimen | ||||
 RIC | 68.6% (55.2–85.2%) | 64.9% (51.7–81.5%) | 17% (7.0–30%) | 18% (8.4–31%) |
 MAC | 78.3% (70.6–86.9%) | 75.7% (66.6–83.7%) | 10% (5.2–18%) | 15% (9.0–22%) |
 P-value | 0.091 | 0.113 | 0.050 | 0.774 |